Source: Eur Respir J, 58 (2) 2003393; 10.1183/13993003.03393-2020
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
William W. Busse, Monica Kraft, Klaus F. Rabe, Yamo Deniz, Paul J. Rowe, Marcella Ruddy, Mario Castro. Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation. Eur Respir J, 58 (2) 2003393; 10.1183/13993003.03393-2020

Member's Comments

No comment yet.

Related content which might interest you: The role of infections in the induction of asthma: genetic and inflammatory drivers Source: Annual Congress 2007 - PG24 - GRACE full-day course. From cough to asthma: the role of infection Year: 2007 Anti-IgE treatment, airway inflammation and remodelling in severe allergic asthma: current knowledge and future perspectives Source: Eur Respir Rev 2015; 24: 594-601 Year: 2015 The role of biomarkers in the management of severe asthma Source: International Congress 2019 – Severe asthma guidelines: update 2019 Year: 2019 Local genetic and environmental factors in asthma disease pathogenesis: chronicity and persistence mechanisms Source: Eur Respir J 2007; 29: 793-803 Year: 2007 Metabolic consequences of obesity as an “outside in” mechanism of disease severity in asthma Source: Eur Respir J 2016; 48: 291-293 Year: 2016 Exploitation of anti-inflammatory mechanisms for the treatment of severe asthma Source: Annual Congress 2005 - Mechanisms of resolution of inflammation Year: 2005 Patient characteristics, biomarkers and exacerbation risk in severe, uncontrolled asthma Source: Eur Respir J, 58 (6) 2100413; 10.1183/13993003.00413-2021 Year: 2021 Evidence of early abnormal airways’ inflammation in children with type 1 diabetes Source: Virtual Congress 2021 – Paediatric allergic asthma: novel therapeutics and monitoring approaches Year: 2021 Dupilumab improves patient-reported outcomes in uncontrolled persistent asthma patients with ongoing allergic rhinitis Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 Measuring inflammation inpaediatric severe asthma: biomarkers in clinical practice Source: Breathe, 16 (1) 190301; 10.1183/20734735.0301-2019 Year: 2020 Are a degree of asthma therapy related to asthma control impairment? Source: Eur Respir J 2003; 22: Suppl. 45, 370s Year: 2003 Which are the factors and causes that lead to omalizumab withdrawal in severe asthma patients? Source: International Congress 2018 – New developments in the treatment of asthma Year: 2018 Dupilumab improves lung function and reduces severe exacerbations in uncontrolled persistent asthma patients with ongoing allergic rhinitis Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 Overview and history of different ways of assessing and monitoring inflammatory airway diseases Source: International Congress 2017 – PG6 Assessing and monitoring airway inflammation in asthma and chronic obstructive pulmonary disease Year: 2017 The challenge of treating uncontrolled asthma on Step 3 and higher: Comparing options Source: International Congress 2015 – The challenge of treating uncontrolled asthma on Step 3 and higher: Comparing options Year: 2015 Dupilumab reduces blood and nasal biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyps with and without comorbid asthma: SINUS-52 trial Source: Virtual Congress 2020 – Phenotypes of asthma and COPD Year: 2020 Current control, airway inflammation, and subsequent exacerbation in patients with asthma Source: Annual Congress 2010 - Induced sputum in relation: a fresh look on phenotyping and monitoring Year: 2010 Distribution of biomarkers in severe asthma and severe uncontrolled asthma Source: Virtual Congress 2021 – Pearls in asthma and respiratory burden research Year: 2021